<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107219</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2021-11620</org_study_id>
    <secondary_id>NCI-2021-11620</secondary_id>
    <secondary_id>Pending</secondary_id>
    <secondary_id>UWI21-06-01</secondary_id>
    <secondary_id>P30CA014520</secondary_id>
    <secondary_id>UG1CA242635</secondary_id>
    <nct_id>NCT05107219</nct_id>
  </id_info>
  <brief_title>GCC Agonist Signal in the Small Intestine</brief_title>
  <official_title>Pilot Study of GCC Agonists to Identify a Cyclic-GMP Signal in Duodenal Tissue of Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal&#xD;
      in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug&#xD;
      Administration for the treatment of conditions related to constipation. This trial aims to&#xD;
      see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on&#xD;
      a certain chemical found in the tissue collected from small intestine and how they compare.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess and compare participants randomly assigned 1:1:1 to one of three intervention&#xD;
      arms (plecanatide 3 mg versus linaclotide 145 mcg versus no active agent) with respect to&#xD;
      change in cyclic guanosine monophosphate (cGMP) accumulation in normal appearing duodenal&#xD;
      mucosa specimens.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Characterization and comparison of the following outcomes (in prioritized order):&#xD;
&#xD;
      Ia. cGMP levels in luminal fluid from participants receiving either linaclotide or&#xD;
      plecanatide to fluid from participants receiving no agent.&#xD;
&#xD;
      Ib. Vasodilator stimulated phosphoprotein (VASP) phosphorylation in normal-appearing duodenal&#xD;
      mucosa biopsy specimens from participants receiving either linaclotide or plecanatide to&#xD;
      those specimens from participants receiving no agent.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Comparison of cGMP and VASP phosphorylation between the plecanatide and linaclotide arms.&#xD;
&#xD;
      II. Transcriptome analysis of cellular response (ribonucleic acid [RNA] sequencing analyses)&#xD;
      to define whether GCC ligand exposure induces reproducible changes in duodenal messenger&#xD;
      [m]RNA expression that can served as a reliable biomarker of GCC-cGMP signaling in future&#xD;
      studies.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 3 arms.&#xD;
&#xD;
      ARM I: Patients receive a single dose of plecanatide (3 mg) orally (PO) 60-120 minutes prior&#xD;
      to standard of care esophagogastroduodenoscopy (EGD).&#xD;
&#xD;
      ARM II: Patients receive a single dose of linaclotide (145 mcg) PO 60-120 minutes prior to&#xD;
      standard of care EGD.&#xD;
&#xD;
      ARM III: Patients undergo standard of care EGD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 17, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cyclic guanosine monophosphate (cGMP) levels</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will compare cGMP levels measured in normal-appearing duodenal mucosa biopsy specimens from participants receiving linaclotide or plecanatide to cGMP levels in specimens from participants receiving no active treatment. Will evaluate the difference between the control and each treated arm in cGMP levels using two-tailed two-sample Student t-tests. If necessary, a log transformation or Wilcoxon rank-sum will be used, as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cGMP levels in luminal fluid</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasodilator-stimulated phosphoprotein (VASP) phosphorylation in normal appearing duodenal mucosa</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison pf cGMP and VASP phosphorylation between the plecanatide and linaclotide arms</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cellular response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Transcriptome analysis of cellular response (ribonucleic acid [RNA] sequencing analyses), to define whether guanylyl cyclase C (GCC) ligand exposure induces reproducible changes in duodenal messenger (m)RNA expression that can serve as a reliable biomarker of GCC-cGMP signaling in future studies.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Abdominal Pain</condition>
  <condition>Barrett Esophagus</condition>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Arm I (plecanatide, EGD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a single dose of plecanatide (3 mg) PO 60-120 minutes prior to standard of care EGD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (linaclotide, EGD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a single dose of linaclotide (145 mcg) PO 60-120 minutes prior to standard of care EGD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (EGD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo standard of care EGD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagogastroduodenoscopy</intervention_name>
    <description>Undergo EGD</description>
    <arm_group_label>Arm I (plecanatide, EGD)</arm_group_label>
    <arm_group_label>Arm II (linaclotide, EGD)</arm_group_label>
    <arm_group_label>Arm III (EGD)</arm_group_label>
    <other_name>EGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linaclotide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (linaclotide, EGD)</arm_group_label>
    <other_name>[9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide</other_name>
    <other_name>Linzess</other_name>
    <other_name>MD-1100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plecanatide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (plecanatide, EGD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for clinically indicated esophagogastroduodenoscopy (EGD) for diagnosis of&#xD;
             possible non-duodenal malignancies, for surveillance of Barrett's esophagus, or for&#xD;
             reflux, abdominal pain, or unexplained nausea/vomiting&#xD;
&#xD;
          -  Age &gt;= 18 years of age. Note: Because no dosing or adverse event (AE) data are&#xD;
             currently available on the use of plecanatide or linaclotide in participants &lt; 18&#xD;
             years of age, children are excluded from this study but will be eligible for future&#xD;
             pediatric trials, if applicable&#xD;
&#xD;
          -  Willing to provide mandatory biospecimens as specified in the protocol&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1&#xD;
&#xD;
          -  Not pregnant or breastfeeding, as determined by clinical administration of pregnancy&#xD;
             test prior to EGD procedure. Note: The effects of plecanatide and linaclotide on the&#xD;
             developing human fetus at the recommended therapeutic dose are unknown. For this&#xD;
             reason, women of childbearing potential and men must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for 2 weeks after discontinuing study agent. Should a woman become pregnant&#xD;
             or suspect she is pregnant while participating in this study, she should inform her&#xD;
             study physician immediately. Breastfeeding should be discontinued if the mother is&#xD;
             treated with plecanatide or linaclotide&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment in the past week with plecanatide, linaclotide, or other agent whose&#xD;
             primary mechanism of action is that of a GCC agonist&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition of plecanatide or linaclotide&#xD;
&#xD;
          -  Use of any other investigational agents =&lt; 12 weeks prior to registration&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  History of gastric bypass, gastric sleeve, or bariatric surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S Weinberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Scott A. Waldman</last_name>
      <phone>215-955-6086</phone>
      <email>Scott.waldman@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Scott A. Waldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David S. Weinberg</last_name>
      <phone>215-444-1424</phone>
      <email>David.Weinberg@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>David S. Weinberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linaclotide</mesh_term>
    <mesh_term>Plecanatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

